Targretin (bexarotene)
- Region
- 🇪🇺 EU
- Active substance
- bexarotene
- Company
- H.A.C. Pharma
- Status
- Authorised
- Therapeutic area
- Lymphoma, T-Cell, Cutaneous
- CHMP opinion
- Thu 16 Nov 2000
- EU approval
- Thu 29 Mar 2001
- Application
- EMEA/H/C/000326
- ATC
- L01XF03
- Official record
- www.ema.europa.eu
Indication
Targretin capsules are indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) patients refractory to at least one systemic treatment.
Regulatory milestones
No milestones recorded in the last year.
Follow Targretin
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.